A vaccine targeting mutant IDH1 induces antitumour immunity - PubMed (original) (raw)

. 2014 Aug 21;512(7514):324-7.

doi: 10.1038/nature13387. Epub 2014 Jun 25.

Lukas Bunse 1, Stefan Pusch 2, Felix Sahm 2, Benedikt Wiestler 3, Jasmin Quandt 4, Oliver Menn 5, Matthias Osswald 3, Iris Oezen 6, Martina Ott 6, Melanie Keil 6, Jörg Balß 7, Katharina Rauschenbach 6, Agnieszka K Grabowska 8, Isabel Vogler 9, Jan Diekmann 10, Nico Trautwein 11, Stefan B Eichmüller 4, Jürgen Okun 12, Stefan Stevanović 11, Angelika B Riemer 8, Ugur Sahin 10, Manuel A Friese 13, Philipp Beckhove 4, Andreas von Deimling 2, Wolfgang Wick 3, Michael Platten 6

Affiliations

A vaccine targeting mutant IDH1 induces antitumour immunity

Theresa Schumacher et al. Nature. 2014.

Abstract

Monoallelic point mutations of isocitrate dehydrogenase type 1 (IDH1) are an early and defining event in the development of a subgroup of gliomas and other types of tumour. They almost uniformly occur in the critical arginine residue (Arg 132) in the catalytic pocket, resulting in a neomorphic enzymatic function, production of the oncometabolite 2-hydroxyglutarate (2-HG), genomic hypermethylation, genetic instability and malignant transformation. More than 70% of diffuse grade II and grade III gliomas carry the most frequent mutation, IDH1(R132H) (ref. 3). From an immunological perspective, IDH1(R132H) represents a potential target for immunotherapy as it is a tumour-specific potential neoantigen with high uniformity and penetrance expressed in all tumour cells. Here we demonstrate that IDH1(R132H) contains an immunogenic epitope suitable for mutation-specific vaccination. Peptides encompassing the mutated region are presented on major histocompatibility complexes (MHC) class II and induce mutation-specific CD4(+) T-helper-1 (TH1) responses. CD4(+) TH1 cells and antibodies spontaneously occurring in patients with IDH1(R132H)-mutated gliomas specifically recognize IDH1(R132H). Peptide vaccination of mice devoid of mouse MHC and transgenic for human MHC class I and II with IDH1(R132H) p123-142 results in an effective MHC class II-restricted mutation-specific antitumour immune response and control of pre-established syngeneic IDH1(R132H)-expressing tumours in a CD4(+) T-cell-dependent manner. As IDH1(R132H) is present in all tumour cells of these slow-growing gliomas, a mutation-specific anti-IDH1(R132H) vaccine may represent a viable novel therapeutic strategy for IDH1(R132H)-mutated tumours.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Brain Pathol. 2010 Jan;20(1):245-54 - PubMed
    1. Cancer Discov. 2013 Jul;3(7):730-41 - PubMed
    1. Lancet Neurol. 2010 Jul;9(7):717-26 - PubMed
    1. Bioinformatics. 2008 Jun 1;24(11):1397-8 - PubMed
    1. Cancer Cell. 2010 Mar 16;17(3):225-34 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources